Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -3% Improvement Relative Risk Ventilation -3% ICU admission -4% c19aspirin.com Formiga et al. Aspirin for COVID-19 Favors aspirin Favors control
Formiga, 20,641 patient aspirin prophylaxis PSM study: 3% higher mortality [p=0.48], 3% higher ventilation [p=0.75], and 4% higher ICU admission [p=0.65] https://c19p.org/formiga2
copied to clipboard
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Formiga et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02870-1
29 Nov 2020    Source   PDF   Share   Tweet
Retrospective 20,641 hospitalized patients in Spain, showing no significant difference in outcomes with existing aspirin use.
risk of death, 3.4% higher, RR 1.03, p = 0.48, treatment 1,000 of 3,291 (30.4%), control 874 of 2,885 (30.3%), odds ratio converted to relative risk, propensity score matching.
risk of mechanical ventilation, 3.2% higher, RR 1.03, p = 0.75, treatment 213 of 3,291 (6.5%), control 181 of 2,885 (6.3%), propensity score matching.
risk of ICU admission, 4.2% higher, RR 1.04, p = 0.65, treatment 283 of 3,291 (8.6%), control 238 of 2,885 (8.2%), propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Formiga et al., 11/29/2020, retrospective, USA, North America, peer-reviewed, 24 authors, study period 1 March, 2020 - 1 May, 2021.
Contact: fformiga@bellvitgehospital.cat.
All Studies   Meta Analysis
This PaperAspirinAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit